Product Description
The drug acts as a selective inhibitor of FAAH, which potently increases hippocampal levels of AEA, OEA and PEA in mice.98
Mechanisms of Action: FAAH Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Depressive Disorder, Major|Cancer Pain|Breakthrough Pain
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2011-002557-56 | P2 |
Terminated |
Cancer Pain |
2012-11-24 |
|
| ACT11705 | P2 |
Terminated |
Cancer Pain|Breakthrough Pain |
2012-02-01 |
|
| 2008-001718-26 | P2 |
Completed |
Depressive Disorder, Major |
2010-02-16 |
|
| FIDELIO | P2 |
Completed |
Depressive Disorder, Major |
2010-02-01 |